

# Felix Mahfoud

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/986765/publications.pdf>

Version: 2024-02-01

187  
papers

22,147  
citations

26630

56  
h-index

9345

143  
g-index

197  
all docs

197  
docs citations

197  
times ranked

18812  
citing authors

#	ARTICLE	IF	CITATIONS
1	Use of fixed-dose combination antihypertensives in Germany between 2016 and 2020: an example of guideline inertia. <i>Clinical Research in Cardiology</i> , 2023, 112, 197-202.	3.3	11
2	A drug-induced hypotensive challenge to verify catheter-based radiofrequency renal denervation in an obese hypertensive swine model. <i>Clinical Research in Cardiology</i> , 2022, 111, 595-603.	3.3	6
3	Predictors of blood pressure response to ultrasound renal denervation in the RADIANCE-HTN SOLO study. <i>Journal of Human Hypertension</i> , 2022, 36, 629-639.	2.2	14
4	Effects of face masks on performance and cardiorespiratory response in well-trained athletes. <i>Clinical Research in Cardiology</i> , 2022, 111, 264-271.	3.3	27
5	Arterial hypertension – Clinical trials update 2021. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2022, 32, 21-31.	2.6	42
6	Renal Artery Variations in Patients With Mild-to-Moderate Hypertension From the RADIANCE-HTN SOLO Trial. <i>Cardiovascular Revascularization Medicine</i> , 2022, 39, 58-65.	0.8	3
7	Sex Differences in Cardiovascular Research: A Scientometric Analysis. <i>Journal of the American Heart Association</i> , 2022, 11, e021522.	3.7	4
8	Morphometric analysis of the human common hepatic artery reveals a rich and accessible target for sympathetic liver denervation. <i>Scientific Reports</i> , 2022, 12, 1413.	3.3	1
9	Renal Denervation Prevents Atrial Arrhythmogenic Substrate Development in CKD. <i>Circulation Research</i> , 2022, 130, 814-828.	4.5	7
10	Drug-coated balloons for small coronary artery disease in patients with chronic kidney disease: a pre-specified analysis of the BASKET-SMALL 2 trial. <i>Clinical Research in Cardiology</i> , 2022, 111, 806-815.	3.3	8
11	Clinical Trial Design Principles and Outcomes Definitions for Device-Based Therapies for Hypertension: A Consensus Document From the Hypertension Academic Research Consortium. <i>Circulation</i> , 2022, 145, 847-863.	1.6	28
12	Photoinduced skin reactions of cardiovascular drugs – a systematic review. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2022, 8, 420-430.	3.0	5
13	Liver stiffness as surrogate parameter in emergency assessment for inpatient health care utilization. <i>PLoS ONE</i> , 2022, 17, e0266069.	2.5	0
14	Long-term efficacy and safety of renal denervation in the presence of antihypertensive drugs (SPYRAL). <i>Journal of Hypertension</i> , 2022, 40, 1114-1121.	13.7	114
15	Effects of Medical Face Masks on Physical Performance in Patients With Coronary Artery Disease or Hypertension. <i>American Journal of Cardiology</i> , 2022, 173, 1-7.	1.6	4
16	Drug-Coated Balloon for Small Coronary Artery Disease in Patients With and Without High-Bleeding Risk in the BASKET-SMALL 2 Trial. <i>Circulation: Cardiovascular Interventions</i> , 2022, 15, 101161CIRCINTERVENTIONS121011569.	3.9	17
17	Ischemic Stroke – A Scientometric Analysis. <i>Frontiers in Neurology</i> , 2022, 13, 893121.	2.4	0
18	Arterial hypertension - clinical trials update 2022. <i>Hypertension Research</i> , 2022, , .	2.7	3

#	ARTICLE	IF	CITATIONS
19	Twenty-Four-Hour Pulsatile Hemodynamics Predict Brachial Blood Pressure Response to Renal Denervation in the SPYRAL HTN-OFF MED Trial. <i>Hypertension</i> , 2022, 79, 1506-1514.	2.7	10
20	Cardio-renal interaction - Clinical trials update 2022. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2022, 32, 2451-2458.	2.6	3
21	A Physiologically Based Pharmacokinetic and Pharmacodynamic Model of the CYP3A4 Substrate Felodipine for Drug-Drug Interaction Modeling. <i>Pharmaceutics</i> , 2022, 14, 1474.	4.5	6
22	Empagliflozin Improves Outcomes in Patients With Heart Failure and Preserved Ejection Fraction Irrespective of Age. <i>Journal of the American College of Cardiology</i> , 2022, 80, 1-18.	2.8	21
23	Impact of angiotensin receptor blocker product recalls on antihypertensive prescribing in Germany. <i>Journal of Human Hypertension</i> , 2021, 35, 903-911.	2.2	15
24	Management of patients with combined arterial hypertension and aortic valve stenosis: a consensus document from the Council on Hypertension and Council on Valvular Heart Disease of the European Society of Cardiology, the European Association of Cardiovascular Imaging (EACVI), and the European Association of Percutaneous Cardiovascular Interventions (EAPCI). <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2021, 7, 242-250.	3.0	21
25	Registration of Image Modalities for Analyses of Tissue Samples Using 3D Image Modelling. <i>Proteomics - Clinical Applications</i> , 2021, 15, 1900143.	1.6	4
26	Effect of renal denervation in attenuating the stress of morning surge in blood pressure: post-hoc analysis from the SPYRAL HTN-ON MED trial. <i>Clinical Research in Cardiology</i> , 2021, 110, 725-731.	3.3	17
27	Alcohol-Mediated Renal Sympathetic Neurolysis for the Treatment of Hypertension: The Peregrine Catheter. <i>Cardiovascular Revascularization Medicine</i> , 2021, 24, 77-86.	0.8	4
28	Myocardial infarction in a patient with single coronary artery - rare but real. <i>Journal of Cardiology Cases</i> , 2021, 23, 246-249.	0.5	1
29	Remote Monitoring With Appropriate Reaction to Alerts Was Associated With Improved Outcomes in Chronic Heart Failure. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2021, 14, e008693.	4.8	17
30	Valvular heart disease in patients with chronic kidney disease. <i>Herz</i> , 2021, 46, 228-233.	1.1	10
31	Renal outcomes and blood pressure patterns in diabetic and nondiabetic individuals at high cardiovascular risk. <i>Journal of Hypertension</i> , 2021, 39, 766-774.	0.5	9
32	One-year results of the first-in-man study investigating the Atrial Flow Regulator for left atrial shunting in symptomatic heart failure patients: the PRELIEVE study. <i>European Journal of Heart Failure</i> , 2021, 23, 800-810.	7.1	46
33	The current status of renal denervation for the treatment of arterial hypertension. <i>Progress in Cardiovascular Diseases</i> , 2021, 65, 76-83.	3.1	16
34	Assessing Adherence to Antihypertensive Medication by Means of Dose-Dependent Reference Plasma Concentration Ranges and Ultra-High Performance Liquid Chromatography-Ion Trap Mass Spectrometry Analysis. <i>Molecules</i> , 2021, 26, 1495.	3.8	7
35	Inducibility of atrial fibrillation after catheter ablation predicts recurrences of atrial fibrillation: a meta-analysis. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2021, 44, 667-676.	1.2	3
36	Device Therapy of Hypertension. <i>Circulation Research</i> , 2021, 128, 1080-1099.	4.5	33

#	ARTICLE	IF	CITATIONS
37	Renal denervation for the treatment of ventricular arrhythmias: A systematic review and meta-analysis. <i>Journal of Cardiovascular Electrophysiology</i> , 2021, 32, 1430-1439.	1.7	3
38	Prioritised endpoints for device-based hypertension trials: the win ratio methodology. <i>EuroIntervention</i> , 2021, 16, e1496-e1502.	3.2	12
39	Extra-cardiac targets in the management of cardiometabolic disease: Device-based therapies. <i>ESC Heart Failure</i> , 2021, 8, 3327-3338.	3.1	3
40	Changes in Plasma Renin Activity After Renal Artery Sympathetic Denervation. <i>Journal of the American College of Cardiology</i> , 2021, 77, 2909-2919.	2.8	63
41	Cardiovascular Outcomes According to Polypharmacy and Drug Adherence in Patients with Atrial Fibrillation on Long-Term Anticoagulation (from the RE-LY Trial). <i>American Journal of Cardiology</i> , 2021, 149, 27-35.	1.6	11
42	Ultrasound renal denervation for hypertension resistant to a triple medication pill (RADIANCE-HTN) Tj ETQqO O O rgBT /Overlock 10 Tf 50	13.7	197
43	European Society of Hypertension position paper on renal denervation 2021. <i>Journal of Hypertension</i> , 2021, 39, 1733-1741.	0.5	88
44	Mapping of an atrial tachycardia after Epicorâ„¢ high-intensity focused ultrasound ablation: A case report. <i>Journal of Electrocardiology</i> , 2021, 67, 19-22.	0.9	0
45	Pacemaker-Based Cardiac Neuromodulation Therapy for the Treatment of Hypertension: The New Kid on the Block. <i>Journal of the American Heart Association</i> , 2021, 10, e022622.	3.7	4
46	Dual Antiplatelet Therapy after PCI in Patients at High Bleeding Risk. <i>New England Journal of Medicine</i> , 2021, 385, 1643-1655.	27.0	247
47	Abbreviated Antiplatelet Therapy in Patients at High Bleeding Risk With or Without Oral Anticoagulant Therapy After Coronary Stenting: An Open-Label, Randomized, Controlled Trial. <i>Circulation</i> , 2021, 144, 1196-1211.	1.6	41
48	Effect of Heart Rate on the Outcome of Renal Denervation in Patients With Uncontrolled Hypertension. <i>Journal of the American College of Cardiology</i> , 2021, 78, 1028-1038.	2.8	27
49	A re-examination of the SPYRAL HTN-OFF MED Pivotal trial with respect to the underlying model assumptions. <i>Contemporary Clinical Trials Communications</i> , 2021, 23, 100818.	1.1	3
50	Catheter-based alcohol-mediated renal denervation for the treatment of uncontrolled hypertension: design of two sham-controlled, randomized, blinded trials in the absence (TARGET BP OFF-MED) and presence (TARGET BP I) of antihypertensive medications. <i>American Heart Journal</i> , 2021, 239, 90-99.	2.7	16
51	Long-Term Results up to 12 Months After Catheter-Based Alcohol-Mediated Renal Denervation for Treatment of Resistant Hypertension. <i>Circulation: Cardiovascular Interventions</i> , 2021, 14, e010075.	3.9	8
52	Abstract P154: Win Ratio Methodology Demonstrates Consistency Of Benefit Across Different Blood Pressure Reduction Thresholds Following Renal Denervation In The Spyral Htn-on Med Pilot Study. <i>Hypertension</i> , 2021, 78, .	2.7	0
53	Blood pressure lowering with alcohol-mediated renal denervation using the Peregrine infusion Catheter is independent of injection site location. <i>Catheterization and Cardiovascular Interventions</i> , 2021, 98, E832-E838.	1.7	0
54	Differences in management of telemedicine alerts on weekdays and public holidays: Results from the OptiLink heart failure trial. <i>Journal of Telemedicine and Telecare</i> , 2021, , 1357633X21110393.	2.7	1

#	ARTICLE	IF	CITATIONS
55	Hypertension trials update. Journal of Human Hypertension, 2021, 35, 398-409.	2.2	11
56	Feasibility and efficacy of transcatheter interatrial shunt devices for chronic heart failure: a systematic review and meta-analysis. European Journal of Heart Failure, 2021, 23, 1960-1970.	7.1	14
57	Evaluation and analytical applicability of a novel volumetric absorptive microsampling strategy for adherence monitoring of antihypertensive drugs by means of LC-HRMS/MS. Analytica Chimica Acta, 2021, 1187, 339137.	5.4	7
58	Meta-analysis in renal denervation – Or how to compare apples with oranges?. Cardiovascular Revascularization Medicine, 2021, 34, 119-119.	0.8	1
59	Changes in blood pressure after crossover to ultrasound renal denervation in patients initially treated with sham in the RADIANCE-HTN SOLO trial. EuroIntervention, 2021, 17, e1024-e1032.	3.2	12
60	Update Hypertonie: Fokus auf die renale Denervation. Kardiologie Up2date, 2021, 17, 337-352.	0.0	0
61	Abstract 9463: Effects of Surgical and FFP2 Masks on Cardiopulmonary Exercise Capacity in Patients With Heart Failure. Circulation, 2021, 144, .	1.6	0
62	The Current Status of Devices for the Treatment of Resistant Hypertension. American Journal of Hypertension, 2020, 33, 10-18.	2.0	9
63	Invasive left ventricle pressure-volume analysis: overview and practical clinical implications. European Heart Journal, 2020, 41, 1286-1297.	2.2	124
64	2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. European Heart Journal, 2020, 41, 407-477.	2.2	4,210
65	Contemporary scientometric analyses using a novel web application: the science performance evaluation (SciPE) approach. Clinical Research in Cardiology, 2020, 109, 810-818.	3.3	16
66	Risk prediction with blood pressure during physical activity: A METter of exercise?. European Journal of Preventive Cardiology, 2020, 27, 975-977.	1.8	1
67	One-year clinical outcomes in patients with renal insufficiency after contemporary PCI: data from a multicenter registry. Clinical Research in Cardiology, 2020, 109, 845-856.	3.3	24
68	Long-term efficacy and safety of drug-coated balloons versus drug-eluting stents for small coronary artery disease (BASKET-SMALL 2): 3-year follow-up of a randomised, non-inferiority trial. Lancet, The, 2020, 396, 1504-1510.	13.7	96
69	Randomized trials of invasive cardiovascular interventions that include a placebo control: a systematic review and meta-analysis. European Heart Journal, 2020, 41, 2556-2569.	2.2	16
70	Effects of edoxaban and warfarin on vascular remodeling: Atherosclerotic plaque progression and collateral artery growth. Vascular Pharmacology, 2020, 127, 106661.	2.1	9
71	J-curve revisited. European Heart Journal, 2020, 41, 4283-4283.	2.2	0
72	Atrial fibrillation: selecting patients at risk for cardiovascular events by blood pressure. European Heart Journal, 2020, 41, 4600-4600.	2.2	1

#	ARTICLE	IF	CITATIONS
73	Decline of emergency admissions for cardiovascular and cerebrovascular events after the outbreak of COVID-19. <i>Clinical Research in Cardiology</i> , 2020, 109, 1500-1506.	3.3	50
74	Research in Atrial Fibrillation. <i>JACC: Clinical Electrophysiology</i> , 2020, 6, 1008-1018.	3.2	10
75	Development and implementation of blood pressure screening and referral guidelines for German community pharmacists. <i>Journal of Clinical Hypertension</i> , 2020, 22, 1807-1816.	2.0	4
76	Physiologically Based Pharmacokinetic Modeling of Metoprolol Enantiomers and $\pm$ -Hydroxymetoprolol to Describe CYP2D6 Drug-Gene Interactions. <i>Pharmaceutics</i> , 2020, 12, 1200.	4.5	15
77	12-Month Results From the Unblinded Phase of the RADIANCE-HTN SOLO Trial of Ultrasound Renal Denervation. <i>JACC: Cardiovascular Interventions</i> , 2020, 13, 2922-2933.	2.9	47
78	Cardiovascular outcomes, bleeding risk, and achieved blood pressure in patients on long-term anticoagulation with the thrombin antagonist dabigatran or warfarin: data from the RE-LY trial. <i>European Heart Journal</i> , 2020, 41, 2848-2859.	2.2	25
79	Renal Denervation in High-Risk Patients With Hypertension. <i>Journal of the American College of Cardiology</i> , 2020, 75, 2879-2888.	2.8	80
80	Registries in renal denervation—completing the picture?. <i>Revista Espanola De Cardiologia (English Ed)</i> 0.6	0.0	0
81	Efficacy of catheter-based renal denervation in the absence of antihypertensive medications (SPYRAL) 1444-1451.	13.7	351
82	Adherence to Antihypertensive Drugs Assessed by Hyphenated High-Resolution Mass Spectrometry Analysis of Oral Fluids. <i>Journal of the American Heart Association</i> , 2020, 9, e014180.	3.7	9
83	Off-the-shelf barrier for emergency intubation in the cardiac catheterization laboratory during the coronavirus disease 2019 (COVID-19) pandemic. <i>Clinical Research in Cardiology</i> , 2020, 109, 1507-1509.	3.3	0
84	Changes in Stroke Volume After Renal Denervation. <i>Hypertension</i> , 2020, 75, 707-713.	2.7	11
85	Myocardial reperfusion reverses the J-curve association of cardiovascular risk and diastolic blood pressure in patients with left ventricular dysfunction and heart failure after myocardial infarction: insights from the EPHEBUS trial. <i>European Heart Journal</i> , 2020, 41, 1673-1683.	2.2	39
86	Alcohol-Mediated Renal Denervation Using the Peregrine System Infusion Catheter for Treatment of Hypertension. <i>JACC: Cardiovascular Interventions</i> , 2020, 13, 471-484.	2.9	73
87	Rationale and design of two randomized sham-controlled trials of catheter-based renal denervation in subjects with uncontrolled hypertension in the absence (SPYRAL HTN-OFF MED Pivotal) and presence (SPYRAL HTN-ON MED Expansion) of antihypertensive medications: a novel approach using Bayesian design. <i>Clinical Research in Cardiology</i> , 2020, 109, 289-302.	3.3	28
88	Survival After Coronary Revascularization With Paclitaxel-Coated Balloons. <i>Journal of the American College of Cardiology</i> , 2020, 75, 1017-1028.	2.8	70
89	Reduction of Outflow Tract Obstruction After PCI to Proximal LAD in a Patient With HOCM. <i>JACC: Case Reports</i> , 2020, 2, 384-388.	0.6	2
90	Catheter-based renal denervation as adjunct to pulmonary vein isolation for treatment of atrial fibrillation: a systematic review and meta-analysis. <i>Journal of Hypertension</i> , 2020, 38, 783-790.	0.5	23

#	ARTICLE	IF	CITATIONS
91	Renal Denervation in Daily Practice: If So, How?. High Blood Pressure and Cardiovascular Prevention, 2020, 27, 267-270.	2.2	2
92	Device-based therapies for arterial hypertension. Nature Reviews Cardiology, 2020, 17, 614-628.	13.7	77
93	Where is renal nerve ablation going?. European Heart Journal, 2020, 41, 4538-4540.	2.2	2
94	Confounding Factors in Renal Denervation Trials. Hypertension, 2020, 76, 1410-1417.	2.7	33
95	Research Output and International Cooperation Among Countries During the COVID-19 Pandemic: Scientometric Analysis. Journal of Medical Internet Research, 2020, 22, e24514.	4.3	12
96	Levoatrialâ€œtoâ€œCoronary Sinus Shunting in HeartÂFailure Therapy. JACC: Cardiovascular Interventions, 2020, 13, 1248-1250.	2.9	1
97	â€œDear Doctorâ€•Warning Letter (Rote-Hand-Brief) on Hydrochlorothiazide and Its Impact on Antihypertensive Prescription. Deutsches A&#x0308;rztblatt International, 2020, 117, 687-688.	0.9	2
98	Abstract 12684: Development and Implementation of Blood Pressure Screening and Referral Guidelines for Community Pharmacists. Circulation, 2020, 142, .	1.6	0
99	ESC Council on hypertension position document on the management of hypertensive emergencies. European Heart Journal - Cardiovascular Pharmacotherapy, 2019, 5, 37-46.	3.0	155
100	Aorticorenal Ganglia Pacing. JACC: Cardiovascular Interventions, 2019, 12, 1121-1124.	2.9	1
101	Procedural and Anatomical Determinants of Multielectrode Renal Denervation Efficacy. Hypertension, 2019, 74, 546-554.	2.7	22
102	Changes in 24-Hour Patterns of Blood Pressure in Hypertension Following Renal Denervation Therapy. Hypertension, 2019, 74, 244-249.	2.7	17
103	Renal Denervation for TreatingÂHypertension. JACC: Cardiovascular Interventions, 2019, 12, 1095-1105.	2.9	61
104	Renal Denervation: Is It Ready for Prime Time?. Current Cardiology Reports, 2019, 21, 80.	2.9	10
105	Stereotactic Radiotherapy for RenalÂDenervation. Journal of the American College of Cardiology, 2019, 74, 1710-1713.	2.8	4
106	Looking back and thinking forwards â€” 15 years of cardiology and cardiovascular research. Nature Reviews Cardiology, 2019, 16, 651-660.	13.7	10
107	Renal Denervation Update From theÂInternational Sympathetic NervousÂSystem Summit. Journal of the American College of Cardiology, 2019, 73, 3006-3017.	2.8	74
108	Arteriovenous Fistula, Blood Pressure, and Shunt Flow: A Thin Line That Separates Beneficial From Detrimental Effects. American Journal of Hypertension, 2019, 32, 935-937.	2.0	0

#	ARTICLE	IF	CITATIONS
109	Development and application of a LC-HRMS/MS method for analyzing antihypertensive drugs in oral fluid for monitoring drug adherence. <i>Analytica Chimica Acta</i> , 2019, 1070, 69-79.	5.4	19
110	Six-Month Results of Treatment-Blinded Medication Titration for Hypertension Control After Randomization to Endovascular Ultrasound Renal Denervation or a Sham Procedure in the RADIANCE-HTN SOLO Trial. <i>Circulation</i> , 2019, 139, 2542-2553.	1.6	97
111	Effects of renal denervation on kidney function and long-term outcomes: 3-year follow-up from the Global SYMPPLICITY Registry. <i>European Heart Journal</i> , 2019, 40, 3474-3482.	2.2	189
112	Cardiovascular outcomes and achieved blood pressure in patients with and without diabetes at high cardiovascular risk. <i>European Heart Journal</i> , 2019, 40, 2032-2043.	2.2	47
113	Effects of Arteriovenous Fistula on Blood Pressure in Patients With End-stage Renal Disease: A Systematic Meta-analysis. <i>Journal of the American Heart Association</i> , 2019, 8, e011183.	3.7	28
114	Safety and efficacy of endovascular ultrasound renal denervation in resistant hypertension. <i>Journal of Hypertension</i> , 2019, 37, 1906-1912.	0.5	15
115	Design and rationale of the Management of High Bleeding Risk Patients Post Bioresorbable Polymer Coated Stent Implantation With an Abbreviated Versus Standard DAPT Regimen (MASTER DAPT) Study. <i>American Heart Journal</i> , 2019, 209, 97-105.	2.7	53
116	Ambulatory heart rate reduction after catheter-based renal denervation in hypertensive patients not receiving anti-hypertensive medications: data from SPYRAL HTN-OFF MED, a randomized, sham-controlled, proof-of-concept trial. <i>European Heart Journal</i> , 2019, 40, 743-751.	2.2	70
117	Secondary rise in blood pressure and leg swelling after central arteriovenous anastomosis. <i>Clinical Research in Cardiology</i> , 2019, 108, 574-576.	3.3	4
118	The AFR-PRELIEVE trial: a prospective, non-randomised, pilot study to assess the Atrial Flow Regulator (AFR) in heart failure patients with either preserved or reduced ejection fraction. <i>EuroIntervention</i> , 2019, 15, 403-410.	3.2	48
119	Renal denervation: dark past, bright future?. <i>Cardiovascular Journal of Africa</i> , 2019, 30, 290-296.	0.4	2
120	Anatomical and procedural determinants of ambulatory blood pressure lowering following catheter-based renal denervation using radiofrequency. <i>Cardiovascular Revascularization Medicine</i> , 2018, 19, 845-851.	0.8	11
121	Real-time left ventricular pressure-volume loops during percutaneous central arteriovenous anastomosis. <i>European Heart Journal</i> , 2018, 39, 2330-2331.	2.2	8
122	The association between different features of sleep-disordered breathing and blood pressure: A cross-sectional study. <i>Journal of Clinical Hypertension</i> , 2018, 20, 575-581.	2.0	18
123	Renal sympathetic denervation restores aortic distensibility in patients with resistant hypertension: data from a multi-center trial. <i>Clinical Research in Cardiology</i> , 2018, 107, 642-652.	3.3	17
124	A multinational clinical approach to assessing the effectiveness of catheter-based ultrasound renal denervation: The RADIANCE-HTN and REQUIRE clinical study designs. <i>American Heart Journal</i> , 2018, 195, 115-129.	2.7	64
125	Catheter-based renal denervation in hypertension. <i>Journal of Hypertension</i> , 2018, 36, 41-42.	0.5	4
126	Procedural and anatomical predictors of renal denervation efficacy using two radiofrequency renal denervation catheters in a porcine model. <i>Journal of Hypertension</i> , 2018, 36, 2453-2459.	0.5	11



#	ARTICLE	IF	CITATIONS
127	2018 Practice guidelines for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension. <i>Blood Pressure</i> , 2018, 27, 314-340.	1.5	254
128	Twenty-Four-Hour Ambulatory Blood Pressure Reduction Patterns After Renal Denervation in the SPYRAL HTN-OFF MED Trial. <i>Circulation</i> , 2018, 138, 1602-1604.	1.6	36
129	Catheter-based renal denervation: the next chapter begins. <i>European Heart Journal</i> , 2018, 39, 4144-4149.	2.2	21
130	European Society of Hypertension position paper on renal denervation 2018. <i>Journal of Hypertension</i> , 2018, 36, 2042-2048.	0.5	39
131	Effect of renal denervation on blood pressure in the presence of antihypertensive drugs: 6-month efficacy and safety results from the SPYRAL HTN-ON MED proof-of-concept randomised trial. <i>Lancet, The</i> , 2018, 391, 2346-2355.	13.7	597
132	Endovascular ultrasound renal denervation to treat hypertension (RADIANCE-HTN SOLO): a multicentre, international, single-blind, randomised, sham-controlled trial. <i>Lancet, The</i> , 2018, 391, 2335-2345.	13.7	526
133	2018 ESC/ESH Guidelines for the management of arterial hypertension. <i>European Heart Journal</i> , 2018, 39, 3021-3104.	2.2	6,826
134	Drug-coated balloons for small coronary artery disease (BASKET-SMALL 2): an open-label randomised non-inferiority trial. <i>Lancet, The</i> , 2018, 392, 849-856.	13.7	263
135	Achieved diastolic blood pressure and pulse pressure at target systolic blood pressure (120-140) Tj ETQq1 1 0.784314 rgBT /Overl trials. <i>European Heart Journal</i> , 2018, 39, 3105-3114.	2.2	92
136	Safety and performance of diagnostic electrical mapping of renal nerves in hypertensive patients. <i>EuroIntervention</i> , 2018, 14, e1334-e1342.	3.2	22
137	Comparison of branch and distally focused main renal artery denervation using two different radio-frequency systems in a porcine model. <i>International Journal of Cardiology</i> , 2017, 241, 373-378.	1.7	23
138	Improvement in health-related quality of life after renal sympathetic denervation in real-world hypertensive patients: 12-month outcomes in the Global SYMPLICITY Registry. <i>Journal of Clinical Hypertension</i> , 2017, 19, 833-839.	2.0	11
139	<i>Primum non nocere</i>: the dangers of deferring heart failure therapy. <i>European Journal of Heart Failure</i> , 2017, 19, 1410-1411.	7.1	0
140	Achieved blood pressure and cardiovascular outcomes in high-risk patients: results from ONTARGET and TRANSCEND trials. <i>Lancet, The</i> , 2017, 389, 2226-2237.	13.7	263
141	Blood Pressure Response to Main Renal Artery and Combined Main Renal Artery Plus Branch Renal Denervation in Patients With Resistant Hypertension. <i>Journal of the American Heart Association</i> , 2017, 6, .	3.7	56
142	Reply. <i>Journal of Hypertension</i> , 2017, 35, 200.	0.5	0
143	Comparison of branch and distally focused main renal artery denervation using two different radio-frequency systems in a porcine model. <i>International Journal of Cardiology</i> , 2017, 249, 365.	1.7	1
144	Catheter-based renal denervation in patients with uncontrolled hypertension in the absence of antihypertensive medications (SPYRAL HTN-OFF MED): a randomised, sham-controlled, proof-of-concept trial. <i>Lancet, The</i> , 2017, 390, 2160-2170.	13.7	597

#	ARTICLE	IF	CITATIONS
145	Renal Denervation for Chronic Heart Failure: Background and Pathophysiological Rationale. <i>Korean Circulation Journal</i> , 2017, 47, 9.	1.9	11
146	Renal denervation for treatment of hypertension – will 2017 be the year of enlightenment?. <i>EuroIntervention</i> , 2017, 12, e2163-e2165.	3.2	0
147	Non-adherence to ivabradine and placebo and outcomes in chronic heart failure: an analysis from SHIFT. <i>European Journal of Heart Failure</i> , 2016, 18, 672-683.	7.1	21
148	Device-based Therapy for Hypertension. <i>Current Hypertension Reports</i> , 2016, 18, 61.	3.5	40
149	Effect of Arteriovenous Anastomosis on Blood Pressure Reduction in Patients With Isolated Systolic Hypertension Compared With Combined Hypertension. <i>Journal of the American Heart Association</i> , 2016, 5, .	3.7	22
150	Reduced blood pressure-lowering effect of catheter-based renal denervation in patients with isolated systolic hypertension: data from SYMPLICITY HTN-3 and the Global SYMPLICITY Registry. <i>European Heart Journal</i> , 2016, 38, ehw325.	2.2	104
151	Catheter-based radio-frequency renal nerve denervation lowers blood pressure in obese hypertensive swine model. <i>Journal of Hypertension</i> , 2016, 34, 1854-1862.	0.5	19
152	Renal denervation in patients with heart failure with preserved ejection fraction: end of the beginning?. <i>European Journal of Heart Failure</i> , 2016, 18, 713-715.	7.1	2
153	Effects of catheter-based renal denervation on cardiac sympathetic activity and innervation in patients with resistant hypertension. <i>Clinical Research in Cardiology</i> , 2016, 105, 364-371.	3.3	54
154	The SPYRAL HTN Global Clinical Trial Program: Rationale and design for studies of renal denervation in the absence (SPYRAL HTN OFF-MED) and presence (SPYRAL HTN ON-MED) of antihypertensive medications. <i>American Heart Journal</i> , 2016, 171, 82-91.	2.7	132
155	Impact of Lesion Placement on Efficacy and Safety of Catheter-Based Radiofrequency Renal Denervation. <i>Journal of the American College of Cardiology</i> , 2015, 66, 1766-1775.	2.8	168
156	Blood pressure changes after catheter-based renal denervation are related to reductions in total peripheral resistance. <i>Journal of Hypertension</i> , 2015, 33, 2519-2525.	0.5	40
157	Renal denervation preserves renal function in patients with chronic kidney disease and resistant hypertension. <i>Journal of Hypertension</i> , 2015, 33, 1261-1266.	0.5	103
158	Progression of Kidney Injury and Cardiac Remodeling in Obese Spontaneously Hypertensive Rats: The Role of Renal Sympathetic Innervation. <i>American Journal of Hypertension</i> , 2015, 28, 256-265.	2.0	54
159	First Report of the Global SYMPLICITY Registry on the Effect of Renal Artery Denervation in Patients With Uncontrolled Hypertension. <i>Hypertension</i> , 2015, 65, 766-774.	2.7	172
160	6-Month Outcomes in Patients With Implantable Cardioverter-Defibrillators Undergoing Renal Sympathetic Denervation for the Treatment of Refractory Ventricular Arrhythmias. <i>JACC: Cardiovascular Interventions</i> , 2015, 8, 984-990.	2.9	78
161	Arterial microanatomy determines the success of energy-based renal denervation in controlling hypertension. <i>Science Translational Medicine</i> , 2015, 7, 285ra65.	12.4	57
162	Arteriovenous anastomosis – next panacea for hypertension?. <i>Nature Reviews Cardiology</i> , 2015, 12, 197-198.	13.7	4

#	ARTICLE	IF	CITATIONS
163	Catheter-Based Renal Denervation Reduces Atrial Nerve Sprouting and Complexity of Atrial Fibrillation in Goats. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2015, 8, 466-474.	4.8	61
164	Aldosterone Antagonists and Renal Denervation. <i>Hypertension</i> , 2015, 65, 280-282.	2.7	9
165	Blood pressure reductions following catheter-based renal denervation are not related to improvements in adherence to antihypertensive drugs measured by urine/plasma toxicological analysis. <i>Clinical Research in Cardiology</i> , 2015, 104, 1097-1105.	3.3	76
166	Reduced Effect of Percutaneous Renal Denervation on Blood Pressure in Patients With Isolated Systolic Hypertension. <i>Hypertension</i> , 2015, 65, 193-199.	2.7	109
167	Renal denervation: simply trapped by complexity?. <i>European Heart Journal</i> , 2015, 36, 199-202.	2.2	67
168	Renal sympathetic nerve denervation using intraluminal ultrasound within a cooling balloon preserves the arterial wall and reduces sympathetic nerve activity. <i>EuroIntervention</i> , 2015, 11, 477-484.	3.2	38
169	Efficacy and Safety of Catheter-Based Radiofrequency Renal Denervation in Stented Renal Arteries. <i>Circulation: Cardiovascular Interventions</i> , 2014, 7, 813-820.	3.9	19
170	Effect of renal denervation on left ventricular mass and function in patients with resistant hypertension: data from a multi-centre cardiovascular magnetic resonance imaging trial. <i>European Heart Journal</i> , 2014, 35, 2224-2231.	2.2	140
171	Renal nerve ablation after SYMPPLICITY HTN-3: confused at the higher level?. <i>European Heart Journal</i> , 2014, 35, 1706-1711.	2.2	69
172	Percutaneous renal denervation in patients with treatment-resistant hypertension: final 3-year report of the Symplicity HTN-1 study. <i>Lancet, The</i> , 2014, 383, 622-629.	13.7	556
173	Atrial Autonomic Innervation. <i>Journal of the American College of Cardiology</i> , 2014, 63, 215-224.	2.8	133
174	Renal Denervation for the Treatment of Cardiovascular High Risk-Hypertension or Beyond?. <i>Circulation Research</i> , 2014, 115, 400-409.	4.5	75
175	Catheter-Based Renal Denervation Is No Simple Matter. <i>Journal of the American College of Cardiology</i> , 2014, 64, 644-646.	2.8	68
176	Innervation Patterns May Limit Response to Endovascular Renal Denervation. <i>Journal of the American College of Cardiology</i> , 2014, 64, 1079-1087.	2.8	110
177	Catheter-based renal denervation: treating hypertension or beyond?. <i>Chinese Medical Journal</i> , 2014, 127, 1166-8.	2.3	0
178	Catheter-Based Renal Denervation. <i>JACC: Cardiovascular Interventions</i> , 2013, 6, 1092-1094.	2.9	32
179	Effects of renal sympathetic denervation on heart rate and atrioventricular conduction in patients with resistant hypertension. <i>International Journal of Cardiology</i> , 2013, 167, 2846-2851.	1.7	117
180	Effect of Renal Denervation on Neurohumoral Activation Triggering Atrial Fibrillation in Obstructive Sleep Apnea. <i>Hypertension</i> , 2013, 62, 767-774.	2.7	124

#	ARTICLE	IF	CITATIONS
181	Feasibility of catheter-based renal nerve ablation and effects on sympathetic nerve activity and blood pressure in patients with end-stage renal disease. <i>International Journal of Cardiology</i> , 2013, 168, 2214-2220.	1.7	122
182	Ambulatory Blood Pressure Changes After Renal Sympathetic Denervation in Patients With Resistant Hypertension. <i>Circulation</i> , 2013, 128, 132-140.	1.6	240
183	Renal Denervation in Moderate to Severe CKD. <i>Journal of the American Society of Nephrology: JASN</i> , 2012, 23, 1250-1257.	6.1	322
184	Renal Sympathetic Denervation Reduces Left Ventricular Hypertrophy and Improves Cardiac Function in Patients With Resistant Hypertension. <i>Journal of the American College of Cardiology</i> , 2012, 59, 901-909.	2.8	466
185	Renal Hemodynamics and Renal Function After Catheter-Based Renal Sympathetic Denervation in Patients With Resistant Hypertension. <i>Hypertension</i> , 2012, 60, 419-424.	2.7	289
186	Inadequate Reporting of Concomitant Drug Treatment in Cardiovascular Interventional Head-to-Head Trials. <i>Clinical Cardiology</i> , 2012, 35, 255-256.	1.8	7
187	Trends in Ezetimibe Prescriptions as Monotherapy or Fixed-Dose Combination in Germany 2012-2021. <i>Frontiers in Cardiovascular Medicine</i> , 0, 9, .	2.4	6